B7IG fusion protein

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5580756
SERIAL NO

08219518

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C.gamma.1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BRISTOL-MYERS SQUIBB COMPANYPRINCETON, NJ2048

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brady, William Bothell, WA 44 1353
Damle, Nitin K Renton, WA 32 1177
Ledbetter, Jeffrey A Seattle, WA 120 4171
Linsley, Peter S Seattle, WA 84 2695

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Genentech, Inc. (1)
* 5336603 CD4 adheson variants 174 1992
 
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (1)
* 4399216 Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials 638 1980
 
ROCHE MOLECULAR SYSTEMS, INC. (2)
* 4683202 Process for amplifying nucleic acid sequences 4097 1985
* 4683195 Process for amplifying, detecting, and/or-cloning nucleic acid sequences 3538 1986
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (6)
* 2003/0219,436 Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein 18 2002
* 2004/0054,158 GL50 molecules and uses therefor 5 2002
* 2006/0115,484 Apo-2 receptor 7 2005
* 2006/0084,147 Apo-2 receptor 11 2005
* 2006/0073,570 Apo-2 receptor 11 2005
8435952 Method for retarding progression to definite rheumatoid arthritis in subjects with undifferentiated arthritis 4 2011
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (2)
6682741 .beta.2 microglobulin fusion proteins and high affinity variants 9 2001
* 2004/0091,492 Beta2 microglobulin fusion proteins and high affinity variants 0 2003
 
EMERGENT PRODUCTIVE DEVELOPMENT SEATTLE, LLC. (1)
8409577 Single chain multivalent binding proteins with effector function 7 2007
 
PRESIDENT BIOSYSTEMS (1)
* 2004/0009,528 Protein chips 2 2002
 
NATIONAL TSING HUA UNIVERSITY (1)
* 2002/0102,232 Compositions and methods for induction of active autoimmunity 0 2001
 
BRISTOL-MYERS SQUIBB COMPANY (33)
* 6887471 Method to inhibit T cell interactions with soluble B7 21 1999
* 2002/0031,510 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith 34 2001
7094874 Soluble CTLA4 mutant molecules 30 2001
* 2002/0182,211 Soluble CTLA4 mutant molecules and uses thereof 22 2001
* 2002/0039,577 Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes 28 2001
* 2003/0083,246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule 10 2001
7304033 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules 32 2002
* 2003/0022,836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules 5 2002
7915395 Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell 4 2002
* 2004/0022,787 Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID 40 2003
7311910 Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions 6 2003
* 2005/0169,919 CTLA4 molecules and IL4-binding molecules and uses thereof 4 2003
7541164 Mammalian cell culture processes for protein production 20 2003
7332303 Product quality enhancement in mammalian cell culture processes for protein production 66 2003
* 2005/0084,933 Product quality enhancement in mammalian cell culture processes for protein production 7 2003
* 2005/0019,859 Mammalian ceII culture processes for protein production 12 2003
7307064 Methods for treating cardiovascular disease using a soluble CTLA4 molecule 19 2004
* 2005/0123,539 Methods for treating cardiovascular disease using a soluble CTLA4 molecule 4 2004
7439230 Methods of treatment using CTLA4 mutant molecules 8 2004
7572772 Soluble CTLA4 mutant molecules 4 2007
7700556 Methods of treatment using CTLA4 mutant molecules 6 2007
7671022 Methods for treating cardiovascular disease using a soluble CTLA4 molecule 1 2007
7829534 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules 3 2007
7915222 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis 4 2009
8227420 Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID 3 2010
8148332 Method for treating a rheumatic disease using a soluble TLA4 molecule 3 2011
8785398 Methods of treatment using CTLA4 mutant molecules 0 2011
8497247 Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule 3 2012
8722632 Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule 0 2013
8703718 Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule 0 2013
9012408 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis 0 2013
9296808 Methods for treating scleroderma by administering a soluble CTLA4 molecule 0 2014
9758565 Methods of treatment using CTLA4 mutant molecules 0 2014
 
MAXYGEN, INC. (4)
* 7183376 Variant B7 co-stimulatory molecules 0 2001
* 2003/0138,881 Novel co-stimulatory molecules 6 2001
* 2005/0154,189 Novel co-stimulatory molecules 2 2004
7612170 Co-stimulatory polypeptides 0 2006
 
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (10)
7794710 Methods of enhancing T cell responsiveness 33 2002
* 2003/0039,653 Methods of enhancing T cell responsiveness 31 2002
* 7432351 B7-H1 variants 16 2003
9062112 B7-H1, a novel immunoregulatory molecule 1 2008
* 2009/0274,666 B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE 10 2008
8981063 B7-H1 Antibodies 3 2009
* 2009/0317,368 B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE 11 2009
8747833 B7-H1 and methods of diagnosis, prognosis, and treatment of cancer 3 2011
8460927 B7-H1 antibodies and method of use 5 2011
9803015 Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target 0 2016
 
TRUBION PHARMACEUTICALS (1)
7754209 Binding constructs and methods for use thereof 23 2003
 
DANA-FARBER CANCER INSTITUTE, INC. (4)
* 6071716 DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells 15 1993
6653444 Polypeptides comprising a B7 extracellular domain 6 1995
* 2002/0182,727 Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells 4 2002
* 2006/0233,795 Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells 0 2006
 
TRUBION PHARMACEUTICALS, INC. (7)
* 2005/0238,646 Binding domain-immunoglobulin fusion proteins 89 2005
* 2005/0202,012 Binding domain-immunogloubulin fusion proteins 31 2005
* 2005/0202,023 Binding domain-immunoglobulin fusion proteins 76 2005
* 2005/0202,534 Binding domain-immunoglobulin fusion proteins 79 2005
* 2005/0186,216 Binding domain-immunoglobulin fusion proteins 35 2005
* 2005/0180,970 Binding domain-immunoglobulin fusion proteins 33 2005
* 2005/0175,614 Binding domain-immunoglobulin fusion proteins 76 2005
 
WYETH (3)
7029674 Methods for downmodulating immune cells using an antibody to PD-1 77 2002
8088905 Nucleic acids encoding antibodies against PD-1 8 2009
* 2010/0028,330 METHODS OF UPMODULATING ADAPTIVE IMMUNE RESPONSE USING ANTI-PD1 ANTIBODIES 6 2009
 
Immunex Corporation (7)
* 7244822 BTL-II proteins 0 2003
* 2004/0209,289 BTL-II nucleic acids, proteins, and antibodies 0 2003
7709618 BTL-II nucleic acids 0 2007
* 2009/0142,801 BTL-II NUCLEIC ACIDS 0 2007
8173603 Methods of using BTL-II proteins 0 2010
* 2010/0330,104 METHODS OF USING BTL-II PROTEINS 0 2010
8674078 Methods of using BTL-II proteins 1 2012
 
THE UNITED STATES OF AMERICA (1)
* 2003/0161,827 Therapies that improve graft survival 5 2002
 
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC (2)
* 2003/0133,939 Binding domain-immunoglobulin fusion proteins 171 2002
7754208 Binding domain-immunoglobulin fusion proteins 29 2002
 
GENECRAFT, INC. (1)
* 2004/0058,445 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB 31 2002
 
CANCURE LIMITED ACN 164 438 359 (3)
9050352 Immunomodulating compositions and uses therefor 2 2004
* 2007/0207,161 Immunomodulating Compositions and uses Therefor 38 2004
9770503 Immunomodulating compositions and uses therefor 0 2015
 
ASAHI KASEI KABUSHIKI KAISHA (1)
* 6638741 Differentiation-suppressive polypeptide serrate-2 0 2001
 
Genentech, Inc. (12)
* 2002/0150,993 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same 9 2002
7807153 Apo-2 receptor agonist antibodies 0 2003
* 2004/0009,552 Apo-2 receptor 12 2003
* 2005/0069,983 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same 6 2004
7750118 Apo-2 receptor polypeptides 0 2005
* 2006/0035,334 Apo-2 receptor 11 2005
7749755 Apo-2 receptor polynucleotides 0 2005
7595046 Treatment of cancer using anti-Apo-2 antibodies 2 2005
* 2006/0141,573 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same 6 2005
7939631 APO-2 receptor polypeptides 0 2010
8092799 Antibodies to Apo-2 receptor polypeptides 0 2010
* 2011/0008,354 ANTIBODIES TO APO-2 RECEPTOR POLYPEPTIDES 1 2010
 
APTEVO RESEARCH AND DEVELOPMENT LLC (11)
7829084 Binding constructs and methods for use thereof 18 2003
* 2005/0136,049 Binding constructs and methods for use thereof 74 2003
8106161 Binding domain-immunoglobulin fusion proteins 6 2005
8333966 CD37 immunotherapeutics and uses thereof 6 2009
* 2011/0171,208 CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF 11 2009
9101609 CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof 0 2009
8147835 Binding domain-immunoglobulin fusion proteins 5 2009
8197810 Binding domain-immunoglobulin fusion proteins 3 2010
8188237 Binding domain-immunoglobulin fusion proteins 3 2010
8853366 Binding domain-immunoglobulin fusion proteins 0 2012
9005612 Binding domain-immunoglobulin fusion proteins 6 2012
 
BIOGEN, INC. (17)
7175847 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 6 2000
7192585 CD80 specific antibodies 8 2005
* 2005/0260,205 Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof 0 2005
7425447 Host cells expressing 7C10 and 16C10 CD80-specific antibodies 2 2006
7414123 Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies 0 2006
* 2008/0038,254 Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens 0 2006
* 2006/0275,291 Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens 0 2006
7417128 7C10 and 16C10 CD80-specific antibodies 2 2006
* 2007/0128,185 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 0 2006
7510712 Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies 2 2007
7510713 Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies 0 2007
7501264 Methods of producing 7C10 and 16C10 CD80-specific antibodies 0 2007
7491393 Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies 2 2007
* 2009/0012,271 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 0 2007
* 2009/0010,939 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 0 2007
* 2008/0114,156 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 0 2007
* 2008/0095,769 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 0 2007
 
Valorisation-Recherche, Societe En commandite (1)
* 7446189 Nucleic acids encoding mutant human CD80 and compositions comprising the same 2 2000
 
The United States of America as represented by the Secretary of the Navy (1)
* 6685941 Methods of treating autoimmune disease via CTLA-4Ig 28 1995
 
AMGEN INC. (9)
7435796 Antibodies which bind B7RP1 7 2000
* 8624010 Nucleic acids encoding B7RP1 0 2000
* 7153669 Nucleic acids encoding MK61 receptors 1 2001
* 2002/0150,977 TNF receptor-like molecules and uses thereof 0 2001
* 7569387 Antibody to TNF receptor-like molecules 0 2006
* 2008/0152,651 Novel polypeptides involved in immune response 3 2007
8470317 B7RP-1 antagonists 0 2008
8309083 Polypeptides involved in immune response 0 2010
* 2011/0059,068 POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE 3 2010
 
BIOGEN IDEC INC. (2)
6926895 Treatment of Crohn's disease using anti-CD80 antibodies that do not inhibit the binding of CD80 antigen to CTLA-4 0 2000
* 2009/0124,791 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 0 2008
 
Heska Corporation (2)
7053181 Canine and feline B7-2 proteins, compositions and uses thereof 0 2004
7385045 Canine B7-1 nucleic acid molecules 2 2005
 
Human Genome Sciences, Inc. (2)
* 6261801 Nucleic acids encoding tumor necrosis factor receptor 5 4 1998
7511017 Methods of treatment with TNFR5 0 2005
 
GENETICS INSTITUTE, LLC (6)
7011833 Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent 5 2000
7521532 GL50 polypeptides 7 2002
* 7459544 Nucleic acids encoding B7-2 fusion proteins 1 2003
* 7601813 Anti-GL50 antibodies 7 2005
* 2006/0099,635 Anti-GL50 antibodies 6 2005
7976840 Use of anti-GL50 antibodies for the downmodulation of an immune response 1 2009
* Cited By Examiner